Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

Johnson & Johnson : J&J to work with India on compensation for recalled hip implants

share with twitter share with LinkedIn share with facebook
share via e-mail
09/07/2018 | 12:30pm CET
Security guards stand outside the office of Johnson & Johnson in Mumbai

MUMBAI (Reuters) - Johnson & Johnson (J&J) said it would work with the Indian government to compensate patients who had suffered from hip implants that were recalled by the U.S. healthcare firm eight years ago after data showed high failure rates.

This follows last week's recommendation from a government panel that J&J pay at least 2 million rupees ($27,812) to each patient for the faulty ASR hip implant. The federal government has asked states to help patients get relief soon.

About 93,000 people worldwide received ASR implants which were recalled in 2010. The Indian panel said in its report that about 4,700 of those people were in India.

Given the recent committee report, "we are seeking to work with the Indian government to develop an appropriate process for providing further support and compensation for patients in need", a J&J spokeswoman said in a statement to Reuters, adding the firm was committed to support all ASR patients in India.

Sushobhan Dasgupta, a senior J&J executive in India, has, however, told Indian newspaper Mint that the company "will not pay people who had an ASR implant if they are doing well".

The company is not okay with the methodology used by the Indian panel, Dasgupta told the paper in an interview https://www.livemint.com/Companies/d5JxJ6YLFqLsUu8sRtf2fO/Not-all-hip-implants-faulty-everyone-wont-be-compensated.html published on Friday. The report has "factual inaccuracies" and "the conclusions could also be inaccurate", he added.

In 2013, J&J agreed to pay http://reut.rs/I20AZB nearly $2.5 billion to settle thousands of lawsuits from patients in the United States who said they were injured by the implants.

In India, the company paid $2 million to patients for repeat surgeries and about $250,000 in related diagnostic costs under its ASR reimbursement programme, but the government panel has criticised J&J for offering no compensation.

Metal hip implant systems such as ASR were designed to be more durable than a traditional metal-on-plastic, ball-and-socket design. But many Indian patients suffered adverse reactions to the implant, the panel said.

J&J entered the Indian market in 1947 when it started selling its now-ubiquitous baby powder. It has in recent years faced issues such as price caps on medical devices.

(Reporting by Aditya Kalra, Writing by Krishna N. Das; Editing by Darren Schuettler and Himani Sarkar)

By Aditya Kalra

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
11/17JOHNSON & JOHNSON : gorsky, alex
11/16WISDOM BY KIDS : A New Digital Tool Designed to Turn the Fun Things Kids Say Int..
11/16JOHNSON & JOHNSON : J&J Unit Gets CHMP Positive Opinion for Apalutamide
11/16JOHNSON & JOHNSON : Acuvue Oasys® With Transitions™ Light Intelligent Tech..
11/16JOHNSON & JOHNSON : ACUVUE OASYS with Transitions Light Intelligent Technology N..
11/16TWITTER : Are Southeast Asia's Retailers and Brands 'customer #ready'?
11/16Arena licenses ralinepag to United, moves S1PR1 agonist to center stage
11/16JOHNSON & JOHNSON : New jury fails to reach verdict in J&J South Carolina talc c..
11/14JOHNSON & JOHNSON : Jury clears J&J of liability in California talc cancer case
11/14JOHNSON & JOHNSON : American Corporate Partners Launches Mentoring Initiative fo..
More news
News from SeekingAlpha
11/175% Income Strategy For 2019 And Beyond 
11/16DiaMedica Therapeutics Aims For $15 Million IPO 
11/16European advisory group backs J&J's apalutamide for castration-resistant pros.. 
11/16The Impact Of Dividend Increases Through September Of 2018 
11/15Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q3 2018 Update 
Financials ($)
Sales 2018 81 394 M
EBIT 2018 25 268 M
Net income 2018 17 909 M
Debt 2018 9 990 M
Yield 2018 2,45%
P/E ratio 2018 22,76
P/E ratio 2019 19,39
EV / Sales 2018 4,93x
EV / Sales 2019 4,70x
Capitalization 392 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 148 $
Spread / Average Target 1,3%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.42%391 542
PFIZER19.30%252 358
NOVARTIS6.38%222 056
ROCHE HOLDING LTD.1.54%214 508
MERCK AND COMPANY35.17%197 785
AMGEN10.67%123 735